Patents by Inventor Kendra Carmon

Kendra Carmon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LGR4 specific monoclonal antibodies and methods of their use
    Patent number: 10729781
    Abstract: Isolated or recombinant anti-LGR4 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: August 4, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Qingyun Liu, Xing Gong, Kendra Carmon
  • LGR4 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
    Publication number: 20180369403
    Abstract: Isolated or recombinant anti-LGR4 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Application
    Filed: December 9, 2016
    Publication date: December 27, 2018
    Inventors: Qingyun LIU, Xing GONG, Kendra CARMON
  • Regulation of Wnt/beta-catenin signaling
    Patent number: 9057096
    Abstract: A composition and method for detecting the ability of a compound to modulate the activity of LGR4, LGR5, or LGR6 receptors in a cell. LGR4, LGR5, and LGR6 are capable of activating the Wnt/?-catenin signaling system which plays essential roles in embryonic development and in the self-renewal and maintenance of adult stem cells.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: June 16, 2015
    Assignee: Board of Regents of the University of Texas System
    Inventors: Qingyun Liu, Kendra Carmon, Xing Gong
  • REGULATION OF WNT/BETA-CATENIN SIGNALING
    Publication number: 20130143227
    Abstract: A composition and method for detecting the ability of a compound to modulate the activity of LGR4, LGR5, or LGR6 receptors in a cell. LGR4, LGR5, and LGR6 are capable of activating the Wnt/?-catenin signaling system which plays essential roles in embryonic development and in the self-renewal and maintenance of adult stem cells.
    Type: Application
    Filed: May 18, 2012
    Publication date: June 6, 2013
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Qingyun Lin, Kendra Carmon, Xing Gong